Trial intelligence / Profile preview

Phase 1/2 study of gilteritinib plus induction and consolidation chemotherapy in newly diagnosed FLT3-mutated AML

jRCT2080224925Phase 2Completed

Sponsor

Astellas Pharma

Start

Oct 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules